HC Wainwright & Co. Reiterates Buy on EyePoint Pharmaceuticals, Maintains $27 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Yi Chen has reiterated a 'Buy' rating on EyePoint Pharmaceuticals (NASDAQ:EYPT) and maintained a price target of $27.
July 28, 2023 | 1:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
EyePoint Pharmaceuticals has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $27.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates a positive outlook for EyePoint Pharmaceuticals. This could potentially attract investors, driving up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100